DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Hanauer SB, Sandborn WJ, Dallaire C. et al
Delayed-release oral mesalamine 4.8g/day (800 mg tablets) compared to 2.4g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. 
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie 2007; 21: 827-834  

Download Bibliographical Data

Search in: